May 5, 2025, 12:56

AACR Trailblazer Cancer Research Grants for Mid-Career Investigators

The American Association for Cancer Research (AACR) has announced the 2025 Trailblazer Cancer Research Grants, designed to support mid-career investigators at a pivotal point in their research journey. These grants aim to fund innovative, exploratory, and paradigm-shifting projects that advance our understanding of cancer biology and improve patient outcomes.

Who is eligible?

Applicants must hold a PhD, MD, or equivalent and be at the rank of Associate Professor (tenured or equivalent) by the grant start date of December 1, 2025. They must have received their first NIH R01 or equivalent award no earlier than December 1, 2015, and maintain independent lab space at an academic, medical, or research institution. AACR Active Membership in good standing is required. There are no citizenship restrictions, but applicants must be legally authorized to work in the host institution’s country for the full duration of the grant.

Funding at a glance:

Grants provide 1,000,000 USD over three years to support a wide range of research expenses, including salaries (limited to 20% of the total budget), research staff and trainees, supplies, equipment, and publication fees. Indirect costs are not permitted. An additional $2,000 can be allocated to attend the AACR Annual Meeting’s Grantee Recognition Event.

Key deadlines:

Letter of Intent (LOI): June 12, 2025 (1:00 p.m. U.S. Eastern Time)
Notification of LOI status: August 2025
Full Application (if invited): September 25, 2025
Award Notification: November 2025
Grant Term Begins: December 1, 2025

Where to apply:

Applications are submitted via ProposalCentral. First-time users will need to register and complete their professional profile before submitting an LOI.

For more information:

Visit www.aacr.org/funding or email [email protected].

AACR AACR Trailblazer Grants academic researchers American Association for Cancer Research cancer cancer biology cancer research funding grant opportunity mid-career investigators NIH R01 OncoDaily Oncology proposalCENTRAL Research Grants translational research

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research